<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Bramble: Food and Drug Administration</title>
    <link>https://news.ketelle.co.uk/entities/food-and-drug-administration</link>
    <description>Stories involving Food and Drug Administration, told neutrally, with how each side covers them.</description>
    <language>en-gb</language>
    <atom:link href="https://news.ketelle.co.uk/entities/food-and-drug-administration/feed.xml" rel="self" type="application/rss+xml"/>
    <item>
      <title>Late-stage trials show retatrutide cut body weight by up to about a quarter</title>
      <link>https://news.ketelle.co.uk/stories/late-stage-trial-results-published-for-lilly-s-retatrutide-weight-loss</link>
      <guid isPermaLink="true">https://news.ketelle.co.uk/stories/late-stage-trial-results-published-for-lilly-s-retatrutide-weight-loss</guid>
      <pubDate>Wed, 30 Sep 2026 03:41:26 +0100</pubDate>
      <category>Health</category>
      <description>Eli Lilly's retatrutide produced the largest weight losses yet recorded in drug trials published on 29 September, in the Lancet (type 2 diabetes) and the New England Journal of Medicine (obesity). It is not yet approved anywhere. (5 outlets: 5 left · 0 centre · 0 right)</description>
      <media:content url="https://i.guim.co.uk/img/media/ec126c1ea0e0e77d16f37276000f3ee97eae5125/371_0_1729_1383/master/1729.jpg?width=1200&amp;height=630&amp;quality=85&amp;auto=format&amp;fit=crop&amp;precrop=40:21,offset-x50,offset-y0&amp;overlay-align=bottom%2Cleft&amp;overlay-width=100p&amp;overlay-base64=L2ltZy9zdGF0aWMvb3ZlcmxheXMvdGctZGVmYXVsdC5wbmc&amp;enable=upscale&amp;s=ef96774d7184bbe90a343790259e175f" medium="image"/>
    </item>
  </channel>
</rss>
